NCT06922526 Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes
| NCT ID | NCT06922526 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Haiyan Wang |
| Condition | Tricuspid Regurgitation |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-04 |
| Primary Completion | 2026-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-04 with a primary completion date of 2026-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospitalization and all-cause mortality, significantly impairing patients' quality of life. With technological advancements, physiological pacing modalities have demonstrated superior clinical efficacy and safety profiles compared to conventional pacing methods. This study aims to evaluate predictors of adverse outcomes and TR progression in CIED recipients under different pacing modalities, thereby providing clinical guidance for high-risk patients.
Eligibility Criteria
Inclusion Criteria: 1. Adult patients 2. Patients with an implantable electronic heart device (CIEDs) 3. The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025 Exclusion Criteria: 1. Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation 2. Patients with severe valvular heart disease, congenital heart disease, or arrhythmias 3. Patients with single-chamber pacemakers or poor images
Contact & Investigator
Haiyan Wang, MD
PRINCIPAL INVESTIGATOR
Shandong First Medical University
Frequently Asked Questions
Who can join the NCT06922526 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Tricuspid Regurgitation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06922526 currently recruiting?
Yes, NCT06922526 is actively recruiting participants. Contact the research team at wanghaiyan96@126.com for enrollment information.
Where is the NCT06922526 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT06922526 clinical trial?
NCT06922526 is sponsored by Haiyan Wang. The principal investigator is Haiyan Wang, MD at Shandong First Medical University. The trial plans to enroll 200 participants.